Improving Outcomes and Options
IN.PACT DEBs have demonstrated favourable clinical results, showing restenosis reduction by employing a “leave no implant behind” strategy.
Optimised and Trusted Technology
A proven balloon platform is the foundation of the IN.PACT DEB product family, which is distinguished by rapid drug transfer and consistent quality. The coating process is no exception – Medtronic’s proprietary FreePac coating is backed by robust science.
Leading the Way in Evidence Creation
Medtronic has proven efficacy in both SFA and BTK with its IN.PACT Peripheral DEB products. Additionally, the IN.PACT clinical program is the most robust in the space with 29 ongoing trials and 4,500+ patients under study.